Medavarapu Srinivas, Goyal Nitasha, Anziska Yaacov
Department of Neurocritical care, Mount Sinai and and Department of Neurology, State University of New York Downstate, Brooklyn, NY, USA.
State University of New York Downstate Medical School, Brooklyn, NY, USA.
AIMS Neurosci. 2024 Jun 11;11(2):178-187. doi: 10.3934/Neuroscience.2024011. eCollection 2024.
Acute transverse myelitis (ATM) is an inflammatory disorder caused by many etiologies, from postinfectious to autoimmune. Rarely, ATM cases have been reported after both COVID-19 infection and COVID-19 vaccination. We described our experience with ATM after COVID-19 infection and conducted a literature review.
We reported a case of longitudinally extensive ATM after COVID 19 infection, who also received convalescent plasma therapy, and present a comprehensive literature review of ATM cases reported after COVID-19 infection and COVID-19 vaccination. The literature search was done using PubMed and Google scholar with keywords and selected peer-reviewed articles. The search included all cases from Jan 2020 to Sept 2022.
A total of 60 ATM cases reported association with post COVID 19 infection, and 23 ATM cases reported association with post COVID 19 vaccinations. Among post COVID 19 ATM cases, the mean age was 49 years and the youngest reported was 7-month-old. A total of 55% (33) were longitudinally extensive ATM. The most common symptom was lower extremity weakness. One case was reported as necrotizing myelitis on biopsy, and another case overlapped with syndrome of GBS and longitudinal ATM. No cases reported using convalescent plasma therapy after infection. Almost all the ATM cases were treated with steroids, but some cases needed additional treatment since not all responded adequately. Six cases (10%) responded with steroids plus plasmapheresis, and 5 cases (8%) responded with steroids + IVIG, especially in the pediatric age group. One case reported a positive response after treatment with eculizumab, and another with infliximab. Two cases (3%) remained paraparetic. Among post covid-19 vaccine ATM cases, 4 cases (17%) were reported as longitudinally extensive ATM. Five cases (21%) had symptom onset within a week after vaccination. Almost all reported a response to steroids except for one case which reported fatality after the 58 day after vaccination.
ATM, in the setting of acute COVID-19 infection, has been described in multiple cases and is a rare complication of COVID-19 vaccination.
急性横贯性脊髓炎(ATM)是一种由多种病因引起的炎症性疾病,病因涵盖从感染后到自身免疫性等多种情况。很少有急性横贯性脊髓炎病例在新冠病毒感染和新冠疫苗接种后被报道。我们描述了我们在新冠病毒感染后发生急性横贯性脊髓炎的经验,并进行了文献综述。
我们报告了一例新冠病毒感染后发生纵向广泛急性横贯性脊髓炎的病例,该病例还接受了恢复期血浆治疗,并对新冠病毒感染和新冠疫苗接种后报告的急性横贯性脊髓炎病例进行了全面的文献综述。文献检索使用了PubMed和谷歌学术,关键词检索并筛选了同行评审文章。检索涵盖了2020年1月至2022年9月的所有病例。
共有60例急性横贯性脊髓炎病例报告与新冠病毒感染后相关,23例急性横贯性脊髓炎病例报告与新冠疫苗接种后相关。在新冠病毒感染后急性横贯性脊髓炎病例中,平均年龄为49岁,报告的最年轻患者为7个月大。共有55%(33例)为纵向广泛急性横贯性脊髓炎。最常见的症状是下肢无力。1例活检报告为坏死性脊髓炎,另1例与吉兰 - 巴雷综合征和纵向急性横贯性脊髓炎综合征重叠。感染后没有病例报告使用恢复期血浆治疗。几乎所有急性横贯性脊髓炎病例都接受了类固醇治疗,但由于并非所有病例反应充分,一些病例需要额外治疗。6例(10%)对类固醇加血浆置换有反应,5例(8%)对类固醇 + 静脉注射免疫球蛋白有反应,特别是在儿童年龄组。1例报告使用依库珠单抗治疗后有阳性反应,另1例使用英夫利昔单抗治疗后有阳性反应。2例(3%)仍为截瘫。在新冠疫苗接种后急性横贯性脊髓炎病例中,4例(17%)报告为纵向广泛急性横贯性脊髓炎。5例(21%)在接种疫苗后一周内出现症状。除1例在接种疫苗58天后报告死亡外,几乎所有病例报告对类固醇有反应。
在急性新冠病毒感染背景下的急性横贯性脊髓炎已在多例中被描述,并且是新冠疫苗接种的一种罕见并发症。